Table 3.
Overview of the embryological outcome from the cycles before SARS-CoV-2 infection from the same patient.
| Patient | Age (y) | ART | Treatment protocol | No. of COC | No. of MII (% per COC) | No. of 2PN (% per MII) | No. of embryos of quality 1 and 2 on day 3 (% per 2PN) | No. of embryos of quality 1 and 2 on day 5 (% per 2PN) | Treatment outcome |
|---|---|---|---|---|---|---|---|---|---|
| 3 | 38 | IVF/ICSI | Agonist | 9 | N/A | 7 (77.8)a | 5 (71.5) | 4 (57.1) | Embryo transfer day 5 |
| 4 | 32 | ICSI | Antagonist | 12 | 8 (66.6) | 6 (75.0) | 1 (16.7) | N/A | Embryo transfer day 3 |
| 6 | 31 | ICSI | Antagonist | 2 | 1 (50.0) | 1 (100.0) | 1 (100.0) | N/A | Freeze all embryos day 3 |
| 7 | 39 | ICSI | Antagonist | 18 | 10 (55.5) | 8 (80.0) | 7 (87.5) | 2 (25.0) | Freeze all embryos after trophectoderm biopsy |
| 8 | 39 | ICSI | Antagonist | 15 | 13 (86.7) | 7 (53.8) | 2 (28.6) | N/A | Freeze all embryos day 3 |
| 11 | 31 | ICSI | Modified natural cycle | 1 | 1 (100.0) | 1 (100.0) | 1 (100.0) | N/A | Embryo transfer day 3 |
| 12 | 36 | ICSI | Antagonist | 11 | 10 (90.9) | 7 (70.0) | 3 (42.8) | N/A | Freeze all embryos day 3 |
| 13 | 31 | ICSI | Antagonist | 6 | 6 (100.0) | 5 (83.3) | 5 (100.0) | 0 | Insufficient quality for freezing day 5/6 |
| 15 | 37 | IVF | Antagonist | 5 | N/A | 4 (80.0)a | 2 (50.0) | N/A | Freeze all embryos day 3 |
| 16 | 27 | IVF | Antagonist | 12 | N/A | 10 (83.3)a | 3 (30.0) | 1 (11.1)b | Embryo transfer day 3 and freezing day 5 |
Note: ART = assisted reproductive technology; COC = cumulus-oocyte complex; ICSI = intracytoplasmic sperm injection; IVF = in vitro fertilization; MII = metaphase II oocytes; N/A = not applicable; 2PN = fertilized oocyte.
a
Percentage of 2PN calculated per number of COC.
b
Calculated per number of 2PN minus 1embryo transferred on day 3.